Cargando…

A myeloma cell line established from a patient refractory to thalidomide therapy revealed high-risk cytogenetic abnormalities and produced vascular endothelial growth factor

Detalles Bibliográficos
Autores principales:	Hattori, Y, Du, W, Yamada, T, Ichikawa, D, Matsunami, S, Matsushita, M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674455/ https://www.ncbi.nlm.nih.gov/pubmed/23686003 http://dx.doi.org/10.1038/bcj.2013.13

Ejemplares similares

Thalidomide for the Treatment of Refractory Multiple Myeloma: Association of Plasma Concentrations of Thalidomide and Angiogenic Growth Factors with Clinical Outcome
por: Kakimoto, Tsunayuki, et al.
Publicado: (2002)

The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma
por: Hashimoto, Shigeo, et al.
Publicado: (2016)

Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study
por: Hjorth, Martin, et al.
Publicado: (2012)

Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma
por: Iida, Shinsuke, et al.
Publicado: (2018)

Thalidomide for refractory gastrointestinal bleeding from vascular malformations in patients with significant comorbidities
por: Bayudan, Alexis Mae, et al.
Publicado: (2020)

The VAD Scheme versus Thalidomide plus VAD for Reduction of Vascular Endothelial Growth Factor in Multiple Myeloma: A Meta-Analysis
por: He, Gan-Lin, et al.
Publicado: (2018)

Cytogenetic abnormality in patients with multiple myeloma analyzed by fluorescent in situ hybridization
por: Hu, Ying, et al.
Publicado: (2016)

Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response
por: Abdallah, Nadine, et al.
Publicado: (2020)

Thalidomide and its analogues in the treatment of Multiple Myeloma
por: Latif, Tahir, et al.
Publicado: (2012)

Thalidomide Reduces Vascular Endothelial Growth Factor Immunostaining in Canine Splenic Hemangiosarcoma
por: Bray, Jonathan P., et al.
Publicado: (2020)

Cytogenetic Abnormalities in Multiple Myeloma Patients at a Tertiary Healthcare Center in India
por: Govindasamy, Perumal, et al.
Publicado: (2019)

Ixazomib–Thalidomide–Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma
por: Ludwig, Heinz, et al.
Publicado: (2019)

Review of thalidomide in the treatment of newly diagnosed multiple myeloma
por: Cavallo, Federica, et al.
Publicado: (2007)

Adverse Effects of Thalidomide Administration, in Patients with Myeloma Multiplex?
por: Svetlana Balkanov, Krstevska, et al.
Publicado: (2014)

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX
por: Kaufman, Jonathan L., et al.
Publicado: (2020)

Age and cytogenetic abnormalities()
por: Souza, Cármino Antonio de
Publicado: (2018)

A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma
por: von Lilienfeld-Toal, Marie, et al.
Publicado: (2008)

Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study
por: Greenberg, A J, et al.
Publicado: (2015)

Prognostic Impact of Cytogenetic Abnormalities in Multiple Myeloma: A Retrospective Analysis of 229 Patients
por: Jian, Yuan, et al.
Publicado: (2016)

Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study
por: Greenberg, A J, et al.
Publicado: (2015)

Cytogenetic abnormalities correlate with clinico-biological characteristics in 30 Moroccan multiple myeloma patients
por: Hamdaoui, Hasna, et al.
Publicado: (2023)

Establishment of the Primary Avian Gonadal Somatic Cell Lines for Cytogenetic Studies
por: Pristyazhnyuk, Inna E., et al.
Publicado: (2022)

Reversible Pulmonary Hypertension Related to Thalidomide Treatment for Multiple Myeloma
por: Villa, Antonio, et al.
Publicado: (2011)

Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide
por: Castro, T.B.M., et al.
Publicado: (2016)

Effect of thalidomide on bone marrow angiogenesis in multiple myeloma patients
por: Cury, Priscilla Cury de Camargo, et al.
Publicado: (2020)

Effect of thalidomide on the expression of vascular endothelial growth factor in a rat model of liver regeneration
por: HUNG, KUO-CHEN, et al.
Publicado: (2013)

Anti-Vascular Endothelial Growth Factor Targeting by Curcumin and Thalidomide in Acute Myeloid Leukemia Cells
por: Salemi, Mahdieh, et al.
Publicado: (2017)

Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison
por: Prince, H Miles, et al.
Publicado: (2007)

Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma
por: Hus, Marek, et al.
Publicado: (2011)

Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma
por: Binder, M, et al.
Publicado: (2017)

Aggressive Clinicopathological Course of Myeloma with t(3;16) (q21;q22) Cytogenetic Abnormality
por: Bozkurt, Süreyya, et al.
Publicado: (2019)

Cytogenetic Abnormalities in Multiple Myeloma: Incidence, Prognostic Significance, and Geographic Heterogeneity in Indian and Western Populations
por: Kadam Amare, Pratibha, et al.
Publicado: (2023)

Prognosis of refractory neurosarcoidosis altered by thalidomide: a case report
por: Hoyle, J Chad, et al.
Publicado: (2008)

A Case of Refractory Henoch-Schönlein Purpura Treated with Thalidomide
por: Choi, Soo Jeong, et al.
Publicado: (2002)

Treatment of refractory ulcerative necrobiosis lipoidica diabeticorum with oral thalidomide
por: Shah, Swapnil D., et al.
Publicado: (2016)

Thalidomide in plasma cell balanitis refractory to conventional topical treatment
por: Serrão, Lucas Mariano, et al.
Publicado: (2018)

Biological evaluation of both enantiomers of fluoro-thalidomide using human myeloma cell line H929 and others
por: Tokunaga, Etsuko, et al.
Publicado: (2017)

Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk
por: Weisel, Katja, et al.
Publicado: (2020)

Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogenetics
por: Harrison, Simon J., et al.
Publicado: (2021)

Inhibitory Effects of Arsenic Trioxide and Thalidomide on Angiogenesis and Vascular Endothelial Growth Factor Expression in Leukemia Cells
por: Kian, Mahnaz Mohammadi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_uj0ddvnlhs2mm129p3fcphfcfg